No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Effects of Endogenous Cyclotronic Ionic Resonance (ICR) on Macular Diabetic Edema: Preliminary Results
Abstract
The intent in this research was to verify the effects of the application of low frequency magnetic fields to cases of macular diabetic edema. We treated six patients afflicted by non-proliferating diabetic retinopathy with macular oedema. Quantitative clinical appraisals of the retinal thickness were obtained for the Optical Coherence Tomography (OCT I). None of the cases affected by non-cystoid macular oedema (non-CMO), or with a relevant ischemic component, evidenced by retinal fluorangiography, had further worsening in their clinical course during the treatment. Only one of the patients, who underwent a long treatment period with ICR demonstrated a significant reduction of the macular edema, with no need of other invasive therapeutic procedures (intravitreous injection of triamcinolone and/or laser therapy).
... Biological effects can be achieved with very low electrical currents, 5 multi-frequency low-frequency electromagnetic fields 6 and also through specific devices that induce enhanced cellular function through the process of photo-biomodulation (PBM), which involves administering light with wavelengths typically ranging from red-orange to near-infrared. Light sources include lowlevel laser (LLL) 7 and, more recently, non-coherent light sources like Light Emitting Diodes (LEDs) 8 whose mechanism of action is based on the interaction between light and tissue chromophores. ...
... 14,15 So biological effects could be exerted therefore not only through the interaction between specific chromo acceptors, but plausibly also by intrinsic variations in the molecular and cellular polarity of diseased tissue, in this case the Pigmented epitheliumphotoreceptor complex, as similarly already demonstrated using multifrequency electromagnetic fields. 6 The strength of our study lies in its longitudinal approach and the inclusion of a randomized control group that received blind treatment following an off-label protocol, using custom-assembled glasses with the micro-LED turned off. Examiner bias was minimized by meticulously ensuring identical conditions at each visit for all patients under the supervision of an experienced physician. ...
Background
recently much studies evidenced the potential role of photo-biomodulation (PBM) in patients affected by Age-related Macular Degeneration (AMD). We designed a new wearable device for self-medication that employs the same broadband red light described in literature, but with extremely low irradiance.
Aim
to demonstrate the safety and effectiveness of low-fluence light stimulations emitted by a LED source with appropriate wavelengths through our new device in improving short-term visual function in patients affected by severe non neovascular AMD.
Materials and methods
we prospectively enrolled patients affected by severe non-neovascular AMD with a relative sparing of the foveal region. All the patients were randomly assigned in placebo or in treatment group. The treatment consisted of 10 sessions of 10-min each, using the new device comprised of micro-LEDs that emitted light onto an amorphous support assembled within Metallic eyeglasses. The placebo group blindly underwent the same number of PBM sessions with the micro-LED turned off. Before and after each placebo/treatment sessions all the patients received: optical coherence tomography (OCT), Best-Corrected Visual Acuity (BCVA) and Microperimetry (MP).
Results
no significant differences in the anatomical parameters were observed in the two groups. The MP mean sensitivity and the central visual function both far and near significantly improved in the treated group (respectively p < 0.001, p < 0.001)
Conclusions
our pivotal demonstrated that the LED PBM delivered through our new device is a safe and effective tool for improving short-term visual function in patients affected by severe non-neovascular AMD.
... For example, CMFs were shown to modulate the time course of insulin-like growth factor II (IGF-II) assayed at both 24 and 72 h post exposure in fracture callus obtained from the femurs of Sprague-Dawley rats [45]. More recent studies have described positive clinical effects on a diverse range of medical conditions and disease states [2,8,10,12,35,44,52]. However, these results are based on pilot studies and require additional clinical trials for substantiation. ...
Electromagnetic fields generated by spinal bone growth stimulation devices have been computationally modelled to determine coverage of the lumbar spinal vertebrae. The underlying assumption of these models was that the electric field, but not the magnetic field, was therapeutically relevant. However, there are no published studies examining the therapeutic coverage of spinal fusion sites by stimulators utilizing combined magnetic fields. To assess the coverage, an anatomical model of the vertebrae and discs of the lumbar spine was developed to represent interbody and posterolateral fusion sites. Computer simulations of the induced electromagnetic fields were analysed to determine coverage of the fusion sites. For both interbody and posterolateral fusion models, combined magnetic fields provided 100 % coverage of the fusion sites for all intervertebral disc spaces and for all posterior planes from L1 to L5, respectively. Within the vertebral column, the magnitude of the electric field reached a maximum value of 3.6 × 10(-4) V/m, which is several orders of magnitude less than any reported study demonstrating a biological effect. Given its clinical efficacy, a bone growth stimulator utilizing combined magnetic fields must rely on the action of its magnetic field rather than its electric field for a therapeutic effect.
Tom S. Tenforde A programma tic effort to assess the effects of magneticfield exposure on living organisms and man is under way at the Lawrence Berkeley Laboratory. This program, which is supported by the Division of Biomedical and Environmental Research of the U. S. Department of Energy, has three principal aspects. First, in a project for which I serve as the coordinator, a series of biophysical experiments are being carried out to determine magnetic field effects on molecular, cellular and whole-animal test systems. A second effort, headed by Dr. Thomas Budinger, involves epidemiological studies designed to evaluate potential health effects in groups of scientists and industrial workers who have been occupationally exposed to high magnetic fields. The third project is the establishment of magnetic field exposure guidelines by a six-member committee composed of scientists from through out the U. S. and headed by Dr. Edward Alpen, Director of the Lawrence Berkeley Laboratory Biology and Medicine Division. During the initial phase of this program, it became increasingly clear to all of the scientists involved that it would be a worthwhile effort to hold a Biomagnetic Effects Workshop. There were, in fact, three reasons underlying our decision to sponsor such a conference: First of alL more than a decade has passed since there was a large conference in the United States devoted exclusively to biomagnetic research.
The Early Treatment Diabetic Retinopathy Study (ETDRS) has recently shown that argon laser photocoagulation treatment is beneficial in reducing the risk of visual loss from clinically significant diabetic macular edema. The ETDRS treatment consisted of a combination of focal treatment to individual-leaking microaneurysms and grid treatment to areas of diffuse leakage and capillary nonperfusion. These techniques are described in detail, and the concepts of “clinically significant macular edema” and “treatable lesions” are defined. Guidelines for the application of ETDRS findings to clinical practice are discussed.
Seven hundred forty-four eyes with very severe proliferative diabetic retinopathy (PDR) were followed with conventional management over a two-year period. Decreases in visual acuity were more frequent during the first year of follow-up than during the second, and were related to baseline visual acuity level and retinopathy severity. After two years, visual acuity was less than 5/200 in 45% of eyes with more than four disc areas of new vessels and visual acuity of 10/30 to 10/50 at baseline, but in only 14% of eyes with traction retinal detachment not involving the center of the macula and without active new vessels or fresh vitreous hemorrhage at baseline. Vitrectomy, which was undertaken only if retinal detachment involving the center of the macula occurred or if severe vitreous hemorrhage failed to clear after a one-year waiting period, had been carried out in 25% of eyes after two years of follow-up.
Le Maculopatie: clinica e terapia Fabiano Editore Canelli (AT
- Oftalmologia Quaderni Di